A Phase I/II Study Of NB1011 Administered Intravenously Daily For 5 Days Every 4 Weeks In Fluoropyrimidine-Resistant Metastatic Or Relapsed Colorectal Cancers
Latest Information Update: 03 Nov 2021
At a glance
- Drugs NB 1011 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 20 Sep 2005 New trial record.